NDude Labs Invests in Nutriventia to Accelerate Global Expansion of Proprietary Nutraceutical Ingredients

Mumbai, September 17, 2026: NDude Labs, a healthcare and wellness‑focused investment firm with operations in India and the United States, today announced a strategic growth investment in Nutriventia, a science‑led Indian nutraceutical ingredients company renowned for its clinically validated, proprietary branded ingredients.

The investment will fuel Nutriventia’s next phase of growth by:

• Expanding its clinical R&D pipeline
• Scaling its proprietary delivery technology platform
• Establishing a dedicated US commercial team to strengthen global market reach

Strategic Alignment
For NDude Labs, the investment reflects its strategy of identifying attractive markets first, then backing category‑leading businesses with capital, operating support, and cross‑border expertise.

Nitin Thakor, Managing Director, NDude Labs, stated: “Nutriventia is exactly the kind of business we want to back: science‑led, innovation‑driven, and built in India with the potential to lead globally. The team has combined pharmaceutical‑grade science with consumer insight, and we believe NDude’s cross‑border expertise and our AI‑native Dude Operating System (DOS) can accelerate that growth.”

Nutriventia’s Proprietary Portfolio
Nutriventia’s clinically validated branded ingredients include:

• TurmXTRA – low‑dose turmeric for musculoskeletal and joint health
• CaffXtend – natural caffeine for mental alertness
• Melotime – sustained‑release melatonin for sound sleep
• Ashwanova (Prolanza) – root‑only Ashwagandha for stress relief
• C‑Fence – long‑acting vitamin C
• ALAXTRA – alpha lipoic acid (upcoming launch)

Rajat Mittal Shah, Co‑Founder & Executive Director, Nutriventia: “Every stage of our growth has been anchored in one principle: get the science right first, and the market follows. NDude Labs recognised that our IP is built on hard evidence, not marketing narratives. This partnership allows us to deepen our clinical pipeline while advancing delivery platforms without compromising scientific rigor.”

Vishal Shah, Co‑Founder & Managing Director, Nutriventia: “This investment enables us to aggressively expand our global commercial infrastructure, establish direct leadership in key markets, and deliver our clinically validated branded ingredients to top‑tier wellness brands worldwide.”

Global Market Context
Nutriventia’s ingredients already reach formulators and wellness brands across the United States, Europe, Australia, South Korea, and Japan.

The investment underscores the thesis that India’s pharmaceutical‑grade science base can deliver globally competitive nutraceutical ingredients, at a time when international brands are shifting from commodity supply to evidence‑backed formulations.

According to MarketsandMarkets, the global nutraceutical ingredients market is valued at USD 108.33 billion in 2026, projected to reach USD 161.53 billion by 2031.

Transaction Advisors

• Investec – Financial Advisor
• Cyril Amarchand Mangaldas and Stratage Law Partners – Legal Counsel
• PwC – Due Diligence Advisor

About NDude Labs
NDude Labs is an investment holding company and operating partner focused on building category‑leading healthcare and wellness businesses. Combining patient capital, entrepreneurial expertise, and its proprietary AI‑native Dude Operating System (DOS), NDude Labs helps portfolio companies accelerate growth, improve performance, and build enduring competitive advantage. With a presence in India and the United States, NDude partners with ambitious founders to build globally competitive businesses.

About Nutriventia
Nutriventia develops high‑performance nutraceutical ingredients using proprietary delivery technologies and rigorous science. With over 40 years of pharmaceutical experience, the company addresses industry challenges such as bioavailability, efficacy, and stability, enabling partners to deliver results‑driven solutions. Its growing portfolio includes TurmXTRA, CaffXtend, C‑Fence, Melotime, Prolanza (Ashwanova), and ALAXTRA, all built on the proprietary Nutriventia E.D.G.E. delivery platform.